BrainStorm

About BrainStorm

BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI) is a pioneering biotechnology company focused on developing innovative adult stem cell therapies for neurodegenerative diseases. The company primarily serves patients suffering from conditions such as Amyotrophic Lateral Sclerosis (ALS) and Alzheimer's Disease. Operating in the biopharmaceutical market, BrainStorm employs a business model centered around research and development (R&D), clinical trials, and eventual commercialization of its proprietary treatments. Revenue generation is anticipated through the successful approval and sale of these therapies, as well as potential partnerships and licensing agreements with larger pharmaceutical companies.

BrainStorm's core product, NurOwn®, is an autologous stem cell therapy designed to modulate neuroinflammation and promote neuroprotection. The company has completed Phase 3 clinical trials for ALS and is actively engaged in Phase 2 trials for Alzheimer's Disease. By leveraging its proprietary technology, BrainStorm aims to address significant unmet medical needs and improve patient outcomes.

Key clients include healthcare providers, research institutions, and patients diagnosed with neurodegenerative diseases. The company operates within a highly regulated environment, adhering to stringent clinical and manufacturing standards to ensure the safety and efficacy of its treatments.